NCT02671071 - Prospective Evaluation of Patients With Uterine Cervical Cancer in Brazilian Health Institutions - The EVITA I Study | Biotech Hunter

Enrollment

638

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2021

Conditions

Cervix Cancer

Interventions

BEHAVIORAL

Quality of Life Questionnaire (QLQ)

The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Cervical cancer module (EORTC QLQ-CX24) will be applied to all patients at 0, 3, 6, 12, 24, 36 months.

Trial Locations (16)

Unknown

Fundação Centro de Controle do Câncer do Estado do Amazonas, Manaus

CRIO, Fortaleza

Clínica AMO, Salvador

Hospital Alderona Bello, São Luís

UFMG, Belo Horizonte

Hospital Erasto Gaertner, Curitiba

IMIP, Recife

Hospital São Vicente de Paulo, Passo Fundo

CPO - Hsl/Pucrs, Porto Alegre

Hospital Geral de Roraima, Boa Vista

CEPON, Florianópolis

Centro de Novos Tratamentos Litoral - Itajaí, Itajaí

INCA, Rio de Janeiro

Hospital São José, São Paulo

Instituto Brasileiro de Controle do Câncer - IBCC, São Paulo

CE

HU Walter Cantídeo, Ceará

All Listed Sponsors

collaborator

EVA - Grupo Brasileiro de Tumores Ginecológicos

UNKNOWN

collaborator

Roche Pharma AG

INDUSTRY

lead

Latin American Cooperative Oncology Group

OTHER